Press coverage about NuVasive (NASDAQ:NUVA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuVasive earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 47.2498464431407 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
Shares of NUVA stock traded down $0.50 on Friday, hitting $54.42. The stock had a trading volume of 705,089 shares, compared to its average volume of 605,786. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.48 and a quick ratio of 1.94. The company has a market capitalization of $2,789.46, a P/E ratio of 28.49, a PEG ratio of 1.45 and a beta of 0.38. NuVasive has a one year low of $44.62 and a one year high of $81.68.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Monday, February 26th. The medical device company reported $0.56 earnings per share for the quarter, meeting the consensus estimate of $0.56. The firm had revenue of $271.70 million during the quarter, compared to the consensus estimate of $272.11 million. NuVasive had a return on equity of 13.40% and a net margin of 8.06%. The firm’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. analysts anticipate that NuVasive will post 2.46 earnings per share for the current fiscal year.
Several research firms have commented on NUVA. Needham & Company LLC raised shares of NuVasive from an “underperform” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Thursday, January 4th. Zacks Investment Research raised shares of NuVasive from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. BidaskClub raised shares of NuVasive from a “sell” rating to a “hold” rating in a research note on Friday, December 15th. BMO Capital Markets reaffirmed a “buy” rating and set a $70.00 price objective on shares of NuVasive in a research note on Thursday, December 14th. Finally, BTIG Research set a $74.00 target price on shares of NuVasive and gave the company a “buy” rating in a research note on Wednesday, December 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the stock. NuVasive presently has a consensus rating of “Buy” and a consensus target price of $66.00.
In other news, CEO Gregory T. Lucier acquired 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 6th. The stock was purchased at an average cost of $50.30 per share, for a total transaction of $301,800.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact NuVasive (NUVA) Share Price” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/nuvasive-nuva-earning-somewhat-favorable-news-coverage-analysis-finds.html.
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.